Website profile

Pharmadispatch

News of the Day Anticipated therapies and not-so-anticipated dominate July PBAC agenda GSK brings Melbourne discovered treatment 'home' to Australian patients New government report reveals the emerging impact of generational reform Health department quietly launches major review of blood products supply Budget reveals

  • 32articles · 30d
  • 2+ day agolatest article
  • Aug 17, 2026earliest in window
  • 91%with images
  • 135avg words
articles per day
Categories
  • Medical 30
  • Health 23
  • Health & Wellness 23
  • Business & Industrial 9
  • Science & Technology 4
  • Economy, Business & Finance 3
  • Finance & Business 2
  • Human Interest 1

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

PharmaDispatch
pharmadispatch.com > news > australia-secures-sovereign-viral-vector-manufacturing-as-vvmf-wins-tga-licence

Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence

3+ day, 11+ hour ago   (159+ words) PharmaDispatch Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence A Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced…...

PharmaDispatch
pharmadispatch.com > news > guilt-over-this-enduring-failure-is-the-correct-response

Guilt over this enduring failure is the correct response

4+ day, 5+ hour ago   (157+ words) PharmaDispatch Guilt over this enduring failure is the correct response We live in a wealthy country where this situation has been allowed to persist. Responsibility is not shared equally. Those with the authority to design, operate and change the system…...

PharmaDispatch
pharmadispatch.com > news > one-of-the-review-recommendations-that-should-be-reconsidered-because-of-time

A review recommendation that should be reconsidered because of time

5+ day, 17+ hour ago   (138+ words) PharmaDispatch A review recommendation that should be reconsidered because of time A plan built around expanding the traditional evaluator pipeline, without first testing what AI can absorb, risks locking in permanent headcount and cost against a workload that may shrink…...

PharmaDispatch
pharmadispatch.com > news > bupa-to-discontinue-international-referrals-for-doctors-on-demand-telehealth

Bupa to discontinue international referrals for 'Doctors on Demand' telehealth

6+ day, 19+ min ago   (139+ words) PharmaDispatch Bupa to discontinue international referrals for 'Doctors on Demand' telehealth Vitura Health has updated investors, confirming that Bupa will discontinue its international patient referrals from the Doctors on Demand telehealth business. … Five years, 1,826 days, and we are still going…...

PharmaDispatch
pharmadispatch.com > news > five-years-1826-days-and-we-are-still-going-on-the-hta-review

Five years, 1,826 days, and we are still going on the HTA Review

6+ day, 11+ hour ago   (114+ words) PharmaDispatch Five years, 1,826 days, and we are still going on the HTA Review Today marks the fifth anniversary of former health minister Greg Hunt's announcement that Australia would conduct a review of health technology assessment. … The 'Dispatched' Week in Review…...

PharmaDispatch
pharmadispatch.com > news > astellas-australia-turns-to-rare-disease-leader-guillaume-pfeiffer-for-next-chapter

Astellas Australia turns to rare disease leader Guillaume Pfeiffer for next chapter

1+ week, 6+ day ago   (131+ words) PharmaDispatch Astellas Australia turns to rare disease leader Guillaume Pfeiffer for next chapter Astellas Australia has appointed Guillaume Pfeiffer as its new general manager, bringing more than two decades of experience across specialty medicines, rare diseases, oncology and advanced therapies…...

PharmaDispatch
pharmadispatch.com > news > argent-biopharma-takes-cannepil-into-us-veterinary-regulatory-process

Argent BioPharma takes CannEpil into US veterinary regulatory process

2+ week, 4+ day ago   (126+ words) PharmaDispatch Argent BioPharma takes CannEpil into US veterinary regulatory process Chairman Roby Zomer said the development marked the program’s transition from a commercial agreement into formal engagement with the FDA’s veterinary medicines division. … Australian study finds maternal RSV vaccination offers…...

PharmaDispatch
pharmadispatch.com > news > genetic-signatures-and-microba-explore-merger-to-build-infectious-disease-diagnostics-group

Genetic Signatures and Microba explore merger to build infectious disease diagnostics group

2+ week, 4+ day ago   (142+ words) PharmaDispatch Genetic Signatures and Microba explore merger to build infectious disease diagnostics group Genetic Signatures and Microba Life Sciences have announced they are in preliminary discussions about a potential merger that would combine rapid infectious disease testing with gut microbiome…...

PharmaDispatch
pharmadispatch.com > news > departmental-restructure-separates-pbs-financing-from-pharmacy-services

Departmental restructure formally splits medicines financing from pharmacy services

3+ week, 4+ day ago   (138+ words) PharmaDispatch Departmental restructure formally splits medicines financing from pharmacy services The Department of Health, Disability and Ageing’s recent restructure could signal that officials increasingly view a program like the Pharmaceutical Benefits Scheme as two interlocking systems of financing and service…...